Litigation Details for Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc. (D. Nev. 2016)
✉ Email this page to a colleague
Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc. (D. Nev. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-10-31 |
| Court | District Court, D. Nevada | Date Terminated | 2020-03-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Miranda Mai Du |
| Jury Demand | None | Referred To | Nancy J. Koppe |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 10,016,403; 10,183,020; 10,278,936; 6,720,001; 6,844,013; 7,022,713; 7,619,004; 8,022,106; 8,048,035; 8,293,727; 8,293,728; 8,298,554; 8,318,715; 8,344,011; 8,357,677; 8,367,652; 8,377,920; 8,399,446; 8,415,335; 8,426,399; 8,431,560; 8,440,650; 8,518,929; 8,524,698; 8,546,372; 8,617,594; 8,829,013; 8,952,015 | ||
| Attorneys | Christopher Neil Sipes | ||
| Firms | Michael S. Kasanoff, LLC | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc.
Biologic Drugs cited in Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Amarin Pharma Inc. v. Hikma Pharmaceuticals USA Inc. (D. Nev. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2016-10-31 | 1 | Complaint | U.S. Patent No. 8,293,728 (“the ‘728 Patent”), U.S. Patent No. 8,318,715 (“the 7 ‘715 Patent”), U.…above. 2 33. United States Patent No. 8,293,728, entitled “METHODS OF TREATING 3 HYPERTRIGLYCERIDEMIA… Patent, the ‘335 Patent, the ‘399 Patent, 12 the ‘560 Patent, the ‘650 Patent, the ‘929 Patent, the…of the ‘728 Patent, the ‘715 Patent, the 11 ‘677 Patent, the ‘652 Patent, the ‘920 Patent, the ‘446 Patent…U.S. Patent No. 8,357,677 (“the ‘677 Patent”), U.S. Patent No. 8,367,652 (“the 8 ‘652 Patent”), U.S | External link to document |
| 2017-12-12 | 102 | Response | thirteen patents are all continuations of U.S. Patent No. 8,293,727 (“the ’727 patent”)—a 20 patent listed… patent, the ’715 patent, the ’677 patent, the ’652 patent, the ’920 patent, the ’446 patent, the …21 patent, the ’399 patent, the ’560 patent, the ’650 patent, the ’929 patent, the ’698 patent, and … ’594 patent”) is a continuation of U.S. Patent No. 8,298,554 23 (“the ’554 patent”)—a patent listed… 1 U.S. Patent Nos. 8,293,728 (“the ’728 patent”), 8,318,715 (“the ’715 patent”), 8,357,677 (“ | External link to document |
| 2018-08-10 | 135 | Order | but is discussed. It is U.S. Patent No. 8,293,727 (“the ‘727 28 patent”). …the ‘715 patent”); (3) U.S. Patent No. 8,357,677 (“the ‘677 9 patent”); (4) U.S. Patent No. 8,367,652…“the ‘652 patent”); (5) U.S. Patent No. 10 8,377,920 (“the ‘920 patent”); (6) U.S. Patent No. 8,399,446…“the ‘446 patent”); (7) U.S. 11 Patent No. 8,415,335 (“the ‘335 patent”); (8) U.S. Patent No. 8,426,399… ‘399 12 patent”); (9) U.S. Patent No. 8,431,560 (“the ‘560 patent”); (10) U.S. Patent No. 13 8, | External link to document |
| 2019-08-09 | 234 | asserted patents, Dr. Toth agrees with my focus on the prosecution of U.S. Patent No. 8,293,727 (the “ʼ727…“ʼ727 patent”), which I understand is a previous patent that is related to the asserted patents. (Toth…opinion that the patent examiner, in allowing the ʼ727 patent and the asserted patents to issue, relied…of the ’715 patent, claim 8 of the ’677 patent, claim 8 of the ’652 patent, and claim 6…of the ’335 patent, claim 17 of the ’652 patent, claim 5 of the ’929 patent, and claim | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
